A severe systemic inflammatory reaction following therapy with montelukast (Singulair).
Gøransson
L G
LG
Department of Medicine, Central Hospital of Rogaland, Stavanger, Norway.
Omdal
R
R
D000085:Acetates / Q000009:adverse effects*; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000627:therapeutic use; D018927:Anti-Asthmatic Agents / Q000009:adverse effects*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D003521:Cyclopropanes; D004305:Dose-Response Relationship, Drug; D005260:Female; D005921:Glomerulonephritis / Q000139:chemically induced* / Q000188:drug therapy; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000139:chemically induced* / Q000188:drug therapy; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use; D011804:Quinolines / Q000009:adverse effects*; D013440:Sulfides
D000085:Acetates; D000305:Adrenal Cortex Hormones; D018927:Anti-Asthmatic Agents; D000893:Anti-Inflammatory Agents; D003521:Cyclopropanes; D011804:Quinolines; D013440:Sulfides; D011239:Prednisolone; C093875:montelukast; D008775:Methylprednisolone